According to the National Institute of Neurological Disorder and Stroke, Huntington’s disease arises from genetically programmed degeneration of neurons in brain which may lead to emotional disturbance, uncontrolled movements or loss of intellectual faculties. This abnormality causes the loss of memory and perception. The increasing growth in the pipeline for Huntington’s disease is primarily attributed to the limited number of treatments available, as well as the technical advancements in medical field which are in turn boosting the research and development over gene related diseases. Various gene therapies and cell therapies have been developed, that have proven their efficacy in treatment of Huntington’s disease. The funding from various organization, which are involved in running programs related to spreading awareness regarding Huntington’s disease is another factor which has aided in the growth of pipeline of this disease. Therefore, the pipeline growth of Huntington’s disease is shooting up at a significant rate.
In August 2015, Ionis Pharmaceuticals, Inc. started a Phase I/II clinical trial on drug, ISIS 443139. This trial is a randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered ISIS 443139 in patients with early symptoms of Huntington’s Disease. The study is expected to be completed in November 2017. In June 2016, Azevan Pharmaceuticals Inc. started a Phase I/II clinical study on drug SRX246 to determine its safety, efficacy and activity in patients with Huntington’s disease. This trial is expected to be completed in June 2018. In June 2015, Ultragenyx Pharmaceutical Inc. started a Phase II clinical study to assess the activity of Triheptanoin as an Anaplerotic therapy in Huntington’s disease. This trial is expected to be completed in June 2019.
Request for table of Content at: https://www.psmarketresearch.com/market-analysis/huntington-disease-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of Huntington’s disease therapeutics include, Ionis Pharmaceuticals, Inc., Azevan Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., CHDI Foundation, Inc., GlaxoSmithKline plc, Janssen Research & Development, LLC, Celgene Corporation, Novartis AG, F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Eli Lilly and Company.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)